QQQ   427.32 (-0.75%)
AAPL   181.56 (-0.41%)
MSFT   402.79 (-0.31%)
META   471.75 (-0.33%)
GOOGL   141.12 (+0.43%)
AMZN   167.08 (-1.43%)
TSLA   193.76 (-3.10%)
NVDA   694.52 (-4.35%)
NIO   5.96 (-2.93%)
AMD   165.69 (-4.70%)
BABA   73.15 (-1.03%)
T   16.92 (-0.29%)
F   12.26 (-0.33%)
MU   80.71 (+1.52%)
CGC   3.54 (-7.33%)
GE   148.62 (-0.36%)
DIS   109.44 (-1.94%)
AMC   4.67 (-3.52%)
PFE   27.60 (-0.07%)
PYPL   58.63 (-0.86%)
XOM   102.75 (-0.94%)
QQQ   427.32 (-0.75%)
AAPL   181.56 (-0.41%)
MSFT   402.79 (-0.31%)
META   471.75 (-0.33%)
GOOGL   141.12 (+0.43%)
AMZN   167.08 (-1.43%)
TSLA   193.76 (-3.10%)
NVDA   694.52 (-4.35%)
NIO   5.96 (-2.93%)
AMD   165.69 (-4.70%)
BABA   73.15 (-1.03%)
T   16.92 (-0.29%)
F   12.26 (-0.33%)
MU   80.71 (+1.52%)
CGC   3.54 (-7.33%)
GE   148.62 (-0.36%)
DIS   109.44 (-1.94%)
AMC   4.67 (-3.52%)
PFE   27.60 (-0.07%)
PYPL   58.63 (-0.86%)
XOM   102.75 (-0.94%)
QQQ   427.32 (-0.75%)
AAPL   181.56 (-0.41%)
MSFT   402.79 (-0.31%)
META   471.75 (-0.33%)
GOOGL   141.12 (+0.43%)
AMZN   167.08 (-1.43%)
TSLA   193.76 (-3.10%)
NVDA   694.52 (-4.35%)
NIO   5.96 (-2.93%)
AMD   165.69 (-4.70%)
BABA   73.15 (-1.03%)
T   16.92 (-0.29%)
F   12.26 (-0.33%)
MU   80.71 (+1.52%)
CGC   3.54 (-7.33%)
GE   148.62 (-0.36%)
DIS   109.44 (-1.94%)
AMC   4.67 (-3.52%)
PFE   27.60 (-0.07%)
PYPL   58.63 (-0.86%)
XOM   102.75 (-0.94%)
QQQ   427.32 (-0.75%)
AAPL   181.56 (-0.41%)
MSFT   402.79 (-0.31%)
META   471.75 (-0.33%)
GOOGL   141.12 (+0.43%)
AMZN   167.08 (-1.43%)
TSLA   193.76 (-3.10%)
NVDA   694.52 (-4.35%)
NIO   5.96 (-2.93%)
AMD   165.69 (-4.70%)
BABA   73.15 (-1.03%)
T   16.92 (-0.29%)
F   12.26 (-0.33%)
MU   80.71 (+1.52%)
CGC   3.54 (-7.33%)
GE   148.62 (-0.36%)
DIS   109.44 (-1.94%)
AMC   4.67 (-3.52%)
PFE   27.60 (-0.07%)
PYPL   58.63 (-0.86%)
XOM   102.75 (-0.94%)
NASDAQ:TPTX

Turning Point Therapeutics (TPTX) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$76.01
$76.01
50-Day Range
$74.80
$76.01
52-Week Range
$23.77
$82.20
Volume
4,322 shs
Average Volume
1.14 million shs
Market Capitalization
$3.81 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

TPTX stock logo

About Turning Point Therapeutics Stock (NASDAQ:TPTX)

Turning Point Therapeutics, Inc., a clinical-stage precision oncology biopharmaceutical company, engages in designing and developing therapies that target genetic drivers of cancer. It develops a pipeline of tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in TKI-naïve and TKI-pretreated patients. The company's lead drug candidate repotrectinib is being evaluated in an ongoing Phase 1/2 trial called TRIDENT-1 for the treatment of patients with ROS1+ advanced non-small-cell lung cancer (NSCLC) and patients with ROS1+ and NTRK+ advanced solid tumors. It also develops TPX-0022, a MET/SRC/CSF1R inhibitor, which is in Phase 1 SHIELD-1 clinical trial for patients with advanced solid tumors harboring genetic alterations in MET; TPX-0046, a RET inhibitor that is in 1/2 SWORD-1 clinical trial for patients with advanced solid tumors harboring RET genetic alterations; and TPX-0131, an ALK inhibitor, which is in Phase 1/2 FORGE-1 study for patient with advanced or metastatic TKI-pretreated ALK-positive NSCLC. Turning Point Therapeutics, Inc. was founded in 2013 and is headquartered in San Diego, California.


TPTX Stock News Headlines

Turning Point Brands Inc.
Alzheimer’s: A Turning Point?
The perfect AI stock under $10
Normally, bringing a new drug to market takes an average of 10 years and between $2.5 and $12 billion. However, new AI technology has the potential to make the process up to 1000 times faster. This #1 AI company is at the forefront of it all.
Turning Point Brands Inc (TPB)
Cormorant Asset Management, LP's Net Worth
Solving quadratic equations - Edexcel
Strange Money Secret Used by the Ultra-Wealthy
If you have any money in a U.S. bank account, you need to see this today –  it could help shield your savings through the turbulence ahead.
Turning Point USA
Turning Point Hospital
Turning Point Secondary School
Turning Point Brands raises dividend by 8% to $0.065
See More Headlines
Receive TPTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Turning Point Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/09/2021
Today
2/20/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:TPTX
Fax
N/A
Employees
250
Year Founded
N/A

Profitability

Net Income
$-236,550,000.00
Pretax Margin
-33,959.03%

Debt

Sales & Book Value

Annual Sales
$30.83 million
Book Value
$15.84 per share

Miscellaneous

Free Float
45,768,000
Market Cap
$3.81 billion
Optionable
Not Optionable
Beta
-0.18
The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives















TPTX Stock Analysis - Frequently Asked Questions

How were Turning Point Therapeutics' earnings last quarter?

Turning Point Therapeutics, Inc. (NASDAQ:TPTX) issued its quarterly earnings data on Tuesday, November, 9th. The company reported ($1.34) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.26) by $0.08. The business earned $0.46 million during the quarter. During the same quarter in the prior year, the firm earned ($0.42) EPS.

What other stocks do shareholders of Turning Point Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Turning Point Therapeutics investors own include NVIDIA (NVDA), Main Street Capital (MAIN), OPKO Health (OPK), Boeing (BA), General Motors (GM), AbbVie (ABBV), Gilead Sciences (GILD), GSK (GSK), Johnson & Johnson (JNJ) and Livongo Health (LVGO).

When did Turning Point Therapeutics IPO?

(TPTX) raised $167 million in an IPO on Wednesday, April 17th 2019. The company issued 9,300,000 shares at $18.00 per share. Goldman Sachs, SVB Leerink and Wells Fargo Securities served as the underwriters for the IPO and Canaccord Genuity was co-manager.

This page (NASDAQ:TPTX) was last updated on 2/20/2024 by MarketBeat.com Staff